Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug

Edesa Biotech, Inc.

Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.
Cash and equivalents $7.47M; working capital $6.56M; raised $0.60M via ATM after quarter end.
FDA agreed on primary endpoint for pivotal Phase 3 study of EB05 (paridiprubart) in ARDS patients.
Canadian regulators authorized Phase 2 study of EB06 for vitiligo; Phase 2b topline results for EB01 in ACD reported.
Plans to file IND for Phase 2 study of EB07 in systemic sclerosis (scleroderma).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edesa Biotech, Inc. reported six months ended March 31, 2023 results: net income net loss of $4.67 million, EPS $0.24 per common share.

Period: six months ended March 31, 2023
Net income: net loss of $4.67 million
EPS: $0.24 per common share
Result: reported results

Exact text from the filing

For the six months ended March 31, 2023, Edesa reported a net loss of $4.67 million, or $0.24 per common share, compared to a net loss of $8.95 million, or $0.66 per common share, for the six months ended March 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edesa Biotech, Inc. reported quarter ended March 31, 2023 results: net income net loss of $2.33 million, EPS $0.12 per common share.

Period: quarter ended March 31, 2023
Net income: net loss of $2.33 million
EPS: $0.12 per common share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2023, Edesa reported a net loss of $2.33 million, or $0.12 per common share, compared to a net loss of $4.57 million, or $0.33 per common share, for the quarter ended March 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-006222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.